Veracyte, Inc. Announces Fourth Quarter and Full-Year 2014 Financial Results, Provides 2015 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Veracyte (VCYT) PT Lowered to $11 at Leerink Partners
March 20, 2015 7:57 AM EDTLeerink Partners analyst Dan Leonard maintained an Outperform rating on Veracyte, Inc (NASDAQ: VCYT) but lowered his price target to $11.00 (from $14.00) following Q4 results.
Leonard commented, "VCYT's revenue for 4Q exceeded the Street and our expectations. While test volume growth is... More
Veracyte (VCYT) Misses Q4 EPS by 3c
March 19, 2015 4:06 PM EDTVeracyte (NASDAQ: VCYT) reported Q4 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11.83 million.
Veracyte sees FY2015 revenue of $48-53 million, versus the consensus of $59.1 million.
For earnings history and earnings-related data on Veracyte (VCYT) click here.
... More